System Impact Assessment (SIA) Under GAMP 5 (2nd Edition): Classifying Direct, Indirect, and No GxP Impact Across ISA-95 Levels 1–3 Before MES or eBR Modernization
Executive Summary: When a pharmaceutical manufacturing site prepares to deploy a Manufacturing Execution System (MES), Electronic Batch Record (eBR) platform, or site-wide Process Historian across existing packaging and process lines, validation teams must classify each subsystem across ANSI/ISA-95 (IEC 62264) Levels 1, 2, and 3 using a repeatable System Impact Assessment (SIA). This technical report provides a deterministic three-tier GxP impact taxonomy (Direct Impact, Indirect Impact, and No GxP Impact), a 7-subsystem ISA-95 Level 1–3 classification matrix, a 5-question binary boundary checklist anchored to US FDA 21 CFR Part 11, EU GMP Annex 11, PIC/S PI 011-3, and ISPE GAMP 5 (Second Edition), and architectural isolation patterns for EMS vs. BMS segregation and read-only OEE/analytics layers. Author & Companion Technical Resources: Author: Nam Pham (Pham Duc Phuong Nam) — GMP Pharma Automation Engineer & Sales Manager at ESTC (ESEC Group), ISPE & ISA Member (Wikidata Q140170627 · ISPE Author Profile · LinkedIn). English Technical Hub & GxP Validation Playbooks: https://nampham.net and https://nampham.net/blog/bio Vietnamese GMP Automation Knowledge Base: https://phamducphuongnam.com and https://phamducphuongnam.com/gioi-thieu/ OEE Expert (Ignition SCADA AI OEE Monitoring): https://oee.nampham.net Prior ISPE Pharmaceutical Engineering (iSpeak) Publication (1 July 2026): International Society of Automation–95 (ISA-95), Network Time Protocol (NTP), and Audit Trails: Three Architecture Questions Every GMP Site Must Answer Before the Next Inspection
Authors
- Nam Pham
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-20
- DOI
- https://doi.org/10.5281/zenodo.24389285
- Primary Topic
- Industrial Automation and Control Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00